Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway

Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway

Melanoma is a common skin tumor that causes a high rate of mortality, especially in Europe, North America and Oceania. Immunosuppressants such as anti-PD-1 have been used in the treatment of malignant melanoma, however, nearly 60% of patients do not respond to these treatments. Sema4D, also called C...

Full description

Bibliographic Details
Main Authors: Zhuo Zhang, Duoli Zhang, Fang Wang, Jiao Liu, Yuhong Sun, Songyot Anuchapreeda, Singkome Tima, Zhangang Xiao, Suwit Duangmano
Format: Article
Language:English
Published: PeerJ Inc. 2023-04-01
Series:PeerJ
Subjects:
Sema4D
Melanoma
Nivolumab
PI3K/AKT
PD-1 inhibitor resistance
Online Access:https://peerj.com/articles/15172.pdf

Similar Items

Similar Items